Stock Details
AZN is AstraZeneca PLC's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 66.56$. Average daily volumn in 3 months 5.19M. Market cap 214.50B

Stock symbol : AZN. Exchange : NasdaqGS. Currency : USD
Lastest price : 69.20$. Total volume : 4.36M. Market state POST
Click reload if you want to check the lastest price on market!!!

AstraZeneca PLC (AZN)
Last Price

Previous Close68.64
Day Range68.64-69.22
Bid69.17 x 1.1k
Ask69.19 x 1.3k
Average Volume5.19M
Market Cap214.5B
52 Week Range52.65-72.12
Trailing P/E65.28
Foward P/E16.06
Dividend (Yield %)2.11%
Ex-Dividend Date2023-02-23

Financial Details

According to AstraZeneca PLC's financial reports the company's revenue in 2022 were 44.35B an increase( +18.92%) over the years 2021 revenue that were of 37.42B. In 2022 the company's total earnings were 3.29B while total earnings in 2021 were 112M( +2578.57%).

Loading ...


AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern,... Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Market Cap:
Total Assets:
Total Cash:

News about "AstraZeneca PLC"


AstraZeneca PLC ADR underperforms Tuesday when compared to competitors

Source from : MarketWatch - 2 days ago

The AstraZeneca PLC ADR shed 0.19% to $68.60 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ ...See details»

AstraZeneca Completes KYM Solid Tumors Treatment Deal

Source from : MarketWatch - 21 hours ago

By Michael Susin AstraZeneca PLC said Thursday that it has completed an exclusive global license agreement with KYM Biosciences over the CMG901 treatment ...See details»


AstraZenecaโ€™s Covid Vaccine May Have Posed a Higher Heart Risk for Young Women, Study Shows

Source from : The New York Times - 1 days ago

A new analysis examined deaths in Britain, where the companyโ€™s product was restricted in 2021 because of safety concerns.See details»


UK stocks finish higher as banks, AstraZeneca climb

Source from : Reuters on MSN - 3 days ago

London stocks rose on Monday with the FTSE 100 finishing nearly 1% higher as bank stocks climbed after fears of a global banking meltdown eased, while AstraZeneca rose after it gave a positive update ...See details»

Is AstraZeneca PLC (AZN) a Solid Prospective Investment?

Source from : Yahoo Finance - 10 days ago

Artisan Global Equity Fund highlighted stocks like AstraZeneca PLC (NASDAQ:AZN) in the Q4 2022 investor letter. Headquartered in Cambridge, the United Kingdom, AstraZeneca PLC (NASDAQ:AZN ...See details»

astrazeneca plc

Source from : Fox Business - 7 days ago

AstraZeneca recorded a big jump in revenue on Thursday as it begins to take a profit from its coronavirus vaccine for the first time. Positive clinical trial results for Merck & Co's experimental ...See details»

Is AstraZeneca PLC (AZN) a High Growth Stock?

Source from : Yahoo - 1 month ago

Baron Funds highlighted stocks like AstraZeneca PLC (NASDAQ:AZN) in the Q4 2022 investor letter. Headquartered in Cambridge, the United Kingdom, AstraZeneca PLC (NASDAQ:AZN) is a global ...See details»

Client Profile: AstraZeneca PLC

Source from : - 1 month ago

Alexion Pharmaceuticals $910,000 Katie Jones No Revolving Door Profiles Non Former Members of Congress AstraZeneca Pharmaceuticals $4,260,000 Susie Ahn Revolving Door Profiles Non Former Members of ...See details»


AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review

Source from : YAHOO!Finance - 3 days ago

Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results from the 66-week analysis of Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca Plc's (NASDAQ: AZN) eplontersen in patients with ...See details»

Patients launch legal action against AstraZeneca over its covid-19 vaccine

Source from : BMJ - 2 days ago

Dozens of patients and families are launching legal action against AstraZeneca over a rare side effect of its covid-19 vaccine. Lawyers have sent the company pre-action protocol letters, the first ...See details»

Covid-19: Study reports no significant increase in deaths after vaccination but raises questions over AstraZenecaโ€™s vaccine

Source from : BMJ - 1 days ago

Researchers have found no significant increase in mortality in young people in the 12 weeks after a covid-19 vaccination, when compared with the longer term risk, but reported an increase in cardiac ...See details»


A Look Into AstraZeneca's Debt

Source from : on MSN - 15 days ago

Based on AstraZeneca's balance sheet as of March 7, 2017, long-term debt is at $14.50 billion and current debt is at $2.31 billion, amounting to $16.81 billion in total debt. Adjusted for $5.02 ...See details»


Source from : Finanznachrichten - 2 days ago

Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative ...See details»

AstraZeneca PLC ADR

Source from : Wall Street Journal - 1 year ago

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...See details»